ReviewInternational journal of molecular sciences2021
The Rationale for the Intra-Articular Administration of Clodronate in Osteoarthritis.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Intra-articular injection choice for osteoarthritis: making sense of cell source-an updated systematic review and dual network meta-analysis.Arthritis research & therapy · 2022Pooled it
- Osthole attenuates cartilage degradation and chondrocyte pyroptosis in knee osteoarthritis and is associated with activation of the PI3K/Akt pathway.Molecular biology reports · 2026Article
- Influence of Synovial Fluid Biochemical Markers on Clinical Outcomes Following Arthroscopic and Non-Arthroscopic Patients with Knee Osteoarthritis.Orthopedic reviews · 2026Article
- Advances in the pathology and treatment of osteoarthritis.Journal of advanced research · 2025Review
- Mechanisms of synovial macrophage polarization in osteoarthritis pathogenesis and their therapeutic implications.Frontiers in immunology · 2025Review
- Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health.Current drug targets · 2025Review
- Osteoarthritis: Insights into Diagnosis, Pathophysiology, Therapeutic Avenues, and the Potential of Natural Extracts.Current issues in molecular biology · 2024Review
- Osteoporosis treatment: current drugs and future developments.Frontiers in pharmacology · 2024Review
- Metalloproteases in Pain Generation and Persistence: A Possible Target?Biomolecules · 2023Review
- Therapeutic applications of adipose-derived stromal vascular fractions in osteoarthritis.World journal of stem cells · 2022Review
- Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).Therapeutic advances in musculoskeletal disease · 2022Review
- The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.Drug design, development and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral pharmacological therapeutic approaches have been proposed to manage osteoarthritis (OA), including intra-articular (IA) injections. Although the discovery of clodronate, a bisphosphonate, dates back to the 1960s and the effects of its IA administration have been investigated for decades in animal models, mechanisms of action of this drug are not quite clear, particularly in OA. This scoping review is an overview of the biological as well as the clinical role of clodronic acid in OA.
methodA scoping review based on the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) model was performed to characterize the mechanisms of action of IA clodronate in OA and to evaluate its efficacy from a clinical point of view.
resultsSeveral effects of clodronate have been observed in animal models of OA, including depletion of synovial lining cells that results in reduced production of chemokines (IL-1, TNF- α), growth factors (TGF-β, BMP 2/4), and metalloproteases (MMP 2/3/9); prevention of cartilage damage, synovial hyperplasia, and proteoglycans loss; reduction in joint inflammation, joint swelling, and osteophyte formation. From a clinical perspective, patients with knee OA treated with IA clodronate experienced improvements in pain and joint mobility.
conclusionClodronate appears to have different mechanisms of action interfering with the pathogenic processes contributing to OA development and progression. This intervention demonstrated positive effects for patients affected by knee OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.